

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 May 2023 (19.05.2023)



(10) International Publication Number
WO 2023/086013 A3

(51) International Patent Classification:

A61K 9/14 (2006.01) *A61K 47/18* (2017.01)
A61K 31/4196 (2006.01) *A61P 11/00* (2006.01)
A61K 47/02 (2006.01) *A61P 31/10* (2006.01)

(21) International Application Number:

PCT/SG2022/050738

(22) International Filing Date:

17 October 2022 (17.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202112434X 09 November 2021 (09.11.2021) SG

(71) Applicants: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10, Connexis North Tower, Singapore 138632 (SG). **NATIONAL UNIVERSITY HOSPITAL (SINGAPORE) PTE LTD** [SG/SG]; 1E Kent Ridge Road, #13-00, Singapore 119228 (SG).

(72) Inventors: **HENG, Wen Chien Desmond**; Bioprocessing Technology Institute, 20 Biopolis Way, #06-01, Singapore 138668 (SG). **NG, Say Kong**; Bioprocessing Technology Institute, 20 Biopolis Way, #06-01, Singapore 138668 (SG). **LEE, Sie Huey**; Institute of Chemical and Engineering Sciences, 1 Pesek Road, Jurong Island, Singapore 627833 (SG). **TEO, Woon Pei Jeanette**; National University Hospital (Singapore) Pte Ltd, 1E Kent Ridge Road, #13-00, Singapore 119228 (SG).

(74) Agent: **CHINA SINDA INTELLECTUAL PROPERTY PTE. LTD.**; 133 Cecil Street, #12-01A Keck Seng Tower, Singapore 069535 (SG).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,

TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

20 July 2023 (20.07.2023)

WO 2023/086013 A3

(54) Title: A SALT-BASED ANTIFUNGAL POWDER PLATFORM FORMULATION FOR AEROSOLIZATION

(57) Abstract: The present invention relates to a salt-based antifungal powder platform formulation comprising a sodium salt and L-leucine as excipients to be formulated alongside an antifungal agent to obtain a salt-based antifungal powder formulation, wherein the sodium salt is at a concentration of 5% w/w or less and the L-leucine is at a concentration of 30% w/w.